Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned. She was building her career across the country, saving for a home, and looking forward to a future she had worked hard to create. Then, a stage 3 triple-negative breast cancer diagnosis turned her world upside down, forcing her to put everything on hold and focus solely on treatment.
Despite her nursing background, Vanessa found herself in unfamiliar territory. “I’ve taken care of patients my whole life,” she says. “But I didn’t really know what breast cancer truly entailed.” The initial treatment was swift, but the cancer spread, leading to a metastatic triple-negative breast cancer diagnosis. “When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,” she recalls.
Triple-negative breast cancer is notoriously aggressive, growing and spreading faster than many other types. For about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to halt progression, making the choice of initial therapy critical. This subtype also disproportionately affects younger women and Black and Hispanic women, underscoring the need for accessible education and timely intervention.
Vanessa was determined to understand her options. Historically, metastatic triple-negative breast cancer treatment relied on chemotherapy, which impacts cancer cells more than normal cells. However, her doctor suggested a clinical trial for antibody-drug conjugates (ADCs), a newer class of medicines designed to target specific markers and deliver chemotherapy directly to cancer cells, potentially sparing healthy tissue. Until recently, ADCs were used later in treatment, but now they may be offered as a first-line therapy for some patients.
ADCs have already shown promise in helping keep cancer from growing, offering patients like Vanessa the ability to plan for the future, whether it's a girls' trip or time with family. However, not all ADCs are the same; safety and efficacy vary. While not every patient is eligible, understanding when ADCs may be considered and how they impact daily life can empower patients during discussions with their care team.
Dr. Gregory Vidal, Vanessa's medical oncologist and Director of Clinical Research at West Cancer Center, emphasizes the importance of individualized treatment. “When selecting treatment, it’s important to consider patients’ goals, wishes and needs so that we can try to realistically plan around those,” he says. “All patients are different and may qualify for different ADCs.” He encourages patients to ask questions about treatment goals and advocate for themselves.
Living with metastatic breast cancer often means ongoing treatment to manage the disease and maintain quality of life. Vanessa leaned on her support network, focusing on “faith over fear” and planning outings around her treatments. She advises others to stay positive, ask questions, and be their own advocate. “You definitely have a fight in front of you, but you can get through this,” she says. “You have to do your research and get answers.”
For more stories like Vanessa's and information on ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.
